Two Laser Treatments Can Improve Tumor Ablation Efficiency of Chemophototherapy

Chemophototherapy is an emerging tumor ablation modality that can improve local delivery of chemotherapeutic agents. Long circulating doxorubicin (Dox) in porphyrin-phospholipid (PoP) liposomes (LC-Dox-PoP) has previously been developed as an effective chemophototherapy agent. In the present study, we observed that in mice, LC-Dox-PoP showed enhanced accumulation in human pancreatic tumor xenografts even with suboptimal light doses, as assessed by fluorometric analysis of tissue homogenates and microscopic imaging of Dox and PoP in tumor slices. A second laser treatment, at a time point in which tumors had greater drug accumulation as a result of the first laser treatment, induced potent tumor ablation. Efficacy studies were carried out in two human pancreatic cancer subcutaneous mouse tumor models; MIA PaCa-2 or low-passage patient derived pancreatic cancer xenografts. A single treatment of 3 mg/kg LC-Dox-PoP and an initial 150 J/cm(2) laser treatment 1 h after drug administration, followed by second laser treatment of 50 J/cm(2) 8 h after drug administration, was more effective than a single laser treatment of 200 J/cm(2) at either of those time points. Thus, this study presents proof-of-principle and rationale for using two discrete laser treatments to enhance the efficacy of chemophototherapy.

Automated summary

Chemophototherapy using long circulating doxorubicin in porphyrin-phospholipid liposomes has shown enhanced drug accumulation in human pancreatic tumor xenografts, leading to potent tumor ablation with two discrete laser treatments. These findings provide proof-of-principle and rationale for utilizing multiple laser treatments to improve the efficacy of chemophototherapy.